Navigation Links
New drug candidate reduces blood lipids
Date:3/10/2010

A thyroid-hormone-like substance that works specifically on the liver reduces blood cholesterol with no serious side effects. This according to a clinical trial conducted by researchers from the Swedish medical university Karolinska Institutet, amongst other centres, published today in the top-ranking scientific periodical The New England Journal of Medicine.

High cholesterol levels in the blood are primarily treated with a group of drugs called statins, but they are not always sufficiently effective and higher doses commonly cause adverse reactions. A team of researchers, including scientists from Karolinska Institutet, have now shown in a clinical trial that a new drug substance called eprotirome can reduce blood cholesterol effectively in patients who have already received statins. Patients who were given supplementary medication with eprotirome demonstrated levels of harmful blood fats that were up to 30 per lower than those of patients who received a placebo supplementary treatment.

The trial lasted three months and included a total of 189 patients. It remains to be studied whether the drug candidate will be equally safe and effective for a larger group of patients over a longer period of time.

"This drug could help patients who react adversely to statins or be used as a supplementary treatment for those who don't respond well to them," says Professor Bo Angelin, who led the study.

Eprotirome mimics the natural ability of thyroid hormone to stimulate the metabolism of cholesterol, and exerts its effects exclusively on the liver. The development of similar non-selective drugs has previously been stopped on account of the serious adverse effects they have had on other organ systems (e.g. cardiac dilatation and osteoporosis) or on the physiological regulation of thyroid hormones.

Eprotirome has been developed by pharmaceutical company KaroBio in Huddinge, which is financing and participating in the research.


'/>"/>

Contact: Katarina Sternudd
katarina.sternudd@ki.se
46-852-483-895
Karolinska Institutet
Source:Eurekalert

Related medicine news :

1. Addiction Industry Thrives Amidst Economic Climate, Seeks Certified Candidates
2. Cardiome Announces Investigational Candidate, Vernakalant, Meets Primary Endpoint in European Comparator Study
3. VHGI: VHGI Gold Targets Candidates to Fill Key Advisory Board Position to Evaluate International Mining Acquisitions; Internet Town Hall Meeting Details Emerge, Kitco Gold Coverage Initiated
4. Candidate Potential Report Reduces Risk of Bad Hires
5. Cequent Files its First IND with FDA: CEQ508, a tkRNAi Drug Candidate in Oncology
6. Pitt researchers find candidates for new HIV drugs
7. AlphaRx Presents Company Overview and New Product Candidates at the Rodman Renshaw Healthcare Conference
8. EPIX Pharmaceuticals, Inc. Announces the P2Y2 Gastrointestinal Early Development Candidate Program Will Be Part of the Intellectual Property Offered For Sale at the September 30, 2009 Auction
9. Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy
10. U.S. Senate Candidate Cheryle Jackson: Public Option Critical to Real Health Care Reform
11. DURECT Announces License of ADHD Drug Candidate in Selected Asian and South Pacific Countries to Orient Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... ... of commercial real estate proudly announced that its service-based charitable program, Olshan Outreach, ... members portfolio-wide will continue Olshan Properties’ annual philanthropic tradition in 2016 with the ...
(Date:5/4/2016)... Columbia, MD (PRWEB) , ... May 04, 2016 ... ... Wound, Ostomy and Continence Nurses (WOCN) Society™ and Canadian Association for Enterostomal ... matchmaking, event promotion, time saving and planning tools to attendees and exhibitors for ...
(Date:5/4/2016)... ... 2016 , ... All-Star Insurance of Northeast TX has announced ... their local community. The agency pledges to select a new beneficiary every 60 ... bring awareness to important local causes with fundraising and other support, by forming ...
(Date:5/4/2016)... Island (PRWEB) , ... May 04, 2016 , ... ... in April 2016. SS&A teamed up with one of the top website design ... information portal contains informative legal articles related to the law firm's main practice ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... foundational nutrients that supports cellular and metabolic health. This synergistic combination of omega-3 ... free-form curcumin, along with 150 mg of reduced glutathione and 200 mg of ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... May 4, 2016 Valeritas Holdings, ... an alternative public offering (APO). This was accomplished via ... Valeritas, Inc. and a private placement of approximately 5 ... per share. Under the terms of the ... Valeritas Holdings, Inc. will trade on the OTC Markets ...
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Actinic Keratosis Market ... to their offering.       (Logo: ... Keratosis Market and Competitive Landscape Highlights 2016, ... products, Actinic Keratosis epidemiology, Actinic Keratosis market ...
(Date:5/3/2016)... , May 4, 2016 Research ... "Global Cancer Stem Cell Therapy Market Outlook 2020" ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,Recombinant technology has improved significantly ... expected to be developed in coming years. Many cancer ... Cancer stem cell therapies are also expected to be ...
Breaking Medicine Technology: